SCHEMBL354736

SCHEMBL354736

Cc1ccc(S(=O)(=O)N(C)Cc2csc(NC(=O)NCc3ccc(Cl)c(Cl)c3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 7/20 0.46
ROCK2 O75116 6/20 0.46
NAMPT P43490 6/20 0.43
RORC P51449 1/20 0.43
ALDH1A1 P00352 2/20 0.40
CNR2 P34972 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
SGK1 O00141 1/20 0.39
AKT1 P31749 1/20 0.39
GSK3B P49841 1/20 0.39
LIMK1 P53667 1/20 0.39
TNK2 Q07912 1/20 0.39
DMPK Q09013 1/20 0.39
MYLK Q15746 1/20 0.39
CDC42BPA Q5VT25 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353167 0.87 ROCK1 (0.45) ROCK1ROCK2TRPV1MAPK1SGK1
SCHEMBL3511157 0.85 ROCK1 (0.48) ROCK1ROCK2NAMPTRORCALDH1A1
SCHEMBL352910 0.84 P2RX7 (0.45) ROCK1ROCK2NAMPTALDH1A1MEN1
SCHEMBL4726467 0.84 ROCK1 (0.47) ROCK1ROCK2TRPV1MEN1MAPK1
SCHEMBL3513135 0.83 ROCK1 (0.49) ROCK1ROCK2ALDH1A1TRPV1MEN1
SCHEMBL4725225 0.80 SLC2A1 (0.43) ROCK1ROCK2TRPV1MEN1LMNA
SCHEMBL4777144 0.80 ROCK1 (0.43) ROCK1ROCK2ALDH1A1TRPV1MEN1
SCHEMBL354526 0.80 ROCK1 (0.42) ROCK1ROCK2TRPV1MEN1LMNA
SCHEMBL4776684 0.79 ROCK1 (0.42) ROCK1ROCK2TRPV1MAPK1AKT1
Hydrochloric Acid SCHEMBL4726458 0.79 SLC2A1 (0.43) ROCK1ROCK2TRPV1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA ROCK1 4747/4885ROCK2 4626/4885NAMPT 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.